



Tiglutik™ (riluzole) Oral Suspension
Effective 02/01/2023

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Tiglutik® (riluzole suspension) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

No PA	Drugs that require PA
Rilutek® # (riluzole tablet)	Tiglutik® (riluzole suspension)

This designates a brand-name drug with FDA "A"-rated generic equivalents. PA is required for the brand, unless a particular form of that drug (for example, tablet, capsule or liquid) does not have an FDA "A"-rated generic equivalent.

Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with Tiglutik excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. Diagnosis of amyotrophic lateral sclerosis (ALS)
2. Member age ≥18 years
3. **ONE** of the following:
 - a. Member has severe dysphagia AND is currently utilizing only dosage formulations that can easily be swallowed (*e.g., oral products that are solutions, suspensions, films, or dispersible tablets*)
 - b. Member utilizes tube feeding (J-tube, G-tube) AND the member is unable to utilize crushed tablets (*e.g., prescriber documents dose sticks to tubing, unable to flush, etc.*)
 - c. Medical necessity for use instead of riluzole tablets

4. Appropriate dose

Continuation of Therapy

Reauthorization requires prescriber documentation of **ALL** of the following:

1. **ONE** of the following:
 - a. Member has severe dysphagia AND is currently utilizing only dosage formulations that can easily be swallowed (e.g., solutions, suspensions, films, or dispersible tablets)
 - b. Member utilizes tube feeding (J-tube, G-tube) AND the member is unable to utilize crushed tablets (e.g., prescriber documents dose sticks to tubing, unable to flush, etc.)
 - c. Continued medical necessity for use instead of riluzole tablets
2. Appropriate dose

Limitations

1. Initial and reauthorizations will be granted for 12 months.

References

1. Tiglutik (riluzole) [package insert]. Berwyn (PA): ITF Pharma; 2020 Mar
2. Elman LB, McCluskey L. Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease. In Eichler AF (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2019 [cited 2019 Oct 15]. Available from: <https://www.uptodate.com/contents/search>.
3. National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. Available from: <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/FactSheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet>. [cited 2019 Oct 15].
4. Maragakis NJ, Galvez-Jimenez N. Epidemiology and pathogenesis of amyotrophic lateral sclerosis. In Eichler AF (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2019 [cited 2019 Oct 15]. Available from: <https://www.uptodate.com/contents/search>.
5. Drugs@FDA [database on the Internet]. Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2019 [cited 2019 Oct 15]. Available from: <http://www.accessdata.fda.gov/>.
6. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. *Eur J Neurol*. 2012 Mar;19(3):360-75. doi: 10.1111/j.1468-1331.2011.03501.x. Epub 2011 Sep 14.
7. Galvez-Jimenez N, Goyal NA, Cudkowicz ME. Disease modifying treatment of amyotrophic lateral sclerosis. In Dashe JF (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2019 [cited 2019 Oct 15]. Available from: <https://www.uptodate.com/contents/search>.
8. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forsheew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2009 Oct 13;73(15):1227-33. doi: 10.1212/WNL.0b013e3181bc01a4.
9. Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. *Clin Investig (Lond)*. 2014;4(7):605-618.
10. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). *J Neurol Sci*. 1999 Oct 31;169(1-2):13-21.
11. Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral

- sclerosis patients. *Amyotroph Lateral Scler Frontotemporal Degener.* 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6.
12. Writing Group, On Behalf of the Edaravone (MCI-186) ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener.* 2017 Oct;18(sup1):20-31. doi: 10.1080/21678421.2017.1362000.
 13. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N Engl J Med.* 1994;330(9):585.
 14. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet.* 1996;347(9013):1425.
 15. Keating GM. Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. *Drugs Ther Perspect.* 2016;32(7):282-286.
 16. Onesti E, Schettino I, Gori MC, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. *Front Neurol.* 2017;8:94.
 17. Dyer AM, Smith A. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. *Drug Des Devel Ther.* 2017; 11: 59–64.
 18. Elman LB, McCluskey L. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. In Eichler AF (Ed). *UpToDate [database on the internet].* Waltham (MA): UpToDate; 2019 [cited 2019 Oct 15]. Available from: <https://www.uptodate.com/contents/search>.
 19. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. *J Neurol Sci.* 1994 Jul;124 Suppl:96-107. 28.
 20. Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. *Clin Neurophysiol.* 2008 Mar;119(3):497-503. doi: 10.1016/j.clinph.2007.09.143. Epub 2007 Dec 27

Review History

02/20/19 – Reviewed

07/21/2021 – Reviewed July P&T; separated Comm/Exch vs. MH; update document to include started and stabilized statement,

11/16/2022 – Reviewed and updated for Nov P&T. Matched MH UPPL criteria. Effective 2/1/23

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.